Literature DB >> 7828516

[Hyponatremia of therapeutic origin. Apropos of a case].

F Assal1, F Chauchot.   

Abstract

Recent epidemiologic studies (11) have shown a frequency of 3-5% of hyponatremia in chronic psychiatric patients, characterized by headaches, blurry vision, weakness, cramps, vomiting and sometimes seizures or coma leading to death. The etiopathology of this electrolytic syndrome is still debated and intriguing. Six to 17% of hospitalized patients in psychiatry present primary polydipsia, among which 25-50% develop hyponatremia. Another cause is the syndrome of inappropriate secretion of anti-diuretic hormone, SIADH, which may be due to a number of psychotropic drugs as carbamazepine, thioridazine, amitriptyline, desipramine, haloperidol, chlorpromazine and fluoxetine (1, 2, 7, 9, 15, 18, 24). These medications can be associated with primary polydipsia but not necessarily, and the hyponatremia is reversible after discontinuiting the treatment. We describe a case of hyponatremia possibly related to clomipramine which has been rarely reported in the literature and discuss the relations between hyponatremia, psychosis, and SIADH.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828516

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  4 in total

1.  Effect of COMT Val108/158Met genotype on risk for polydipsia in chronic patients with schizophrenia.

Authors:  Kenji Yamada; Takahiro Shinkai; Hsin-I Chen; Kensuke Utsunomiya; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2014-01-18       Impact factor: 3.843

Review 2.  Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.

Authors:  Didier Meulendijks; Cyndie K Mannesse; Paul A F Jansen; Rob J van Marum; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

3.  Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia.

Authors:  Takahiro Shinkai; Vincenzo De Luca; Kensuke Utsunomiya; Shinichi Sakata; Yoshiaki Inoue; Yuko Fukunaka; Rudi Hwang; Osamu Ohmori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

4.  Serum sodium changes in fluoxetine users at different age groups.

Authors:  Fereshteh Shakibaei; Ali Gholamrezaei; Mahmood Alikhani; Khalil Talaeizadeh
Journal:  Iran J Psychiatry       Date:  2010
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.